Clinical trials: Postmenopausal Flushing
Hot Flashes
Efficacy and Safety of a Topical Estradiol Gel for Treatment of Postmenopausal Symptoms
The purpose of this study is to determine the efficacy and safety of a topical estradiol gel for the treatment of hot flushes in postmenopausal women.
- Trial name
- NCT00391417
- Testing
- estradiol gel
- Volunteers
- 431 people
- Sponsor
- BioSante Pharmaceuticals
Breast Cancer, Hot Flashes
Soy Protein Supplement In Treating Hot Flashes in Postmenopausal Women Receiving Tamoxifen for Breast Disease
RATIONALE: Soy protein supplement may be effective in reducing hot flushes in postmenopausal women who are receiving tamoxifen for breast disease.
- Conditions
- Breast Cancer, Hot Flashes, Hot Flushes
- Trial name
- NCT00031720
- Testing
- soy protein, isoflavones, Tamoxifen
- Where
- 14 sites in United States
- Volunteers
- 112 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Postmenopausal Flushing, Postmenopausal Symptoms
Self-Management Box on Hot Flash in Postmenopausal Women
Aim of the study This study aims to evaluate the effect of a nurse-led menopause self-management box on hot flash frequency and menopause-specific quality of life among postmenopausal women.
- Trial name
- Self-Managemen (NCT07874893)
- Testing
- Components of Nurse-Led Menopause Self- Management Box
- Where
- Egypt
- Volunteers
- 120 people
- Sponsor
- Mansoura University
Hot Flashes
Effect of Dehydroepiandrosterone (DHEA) on Hot Flashes in Postmenopausal Women
The purpose of the study is to evaluate the effect of daily oral intake of DHEA 50 mg for 4 months on reducing vasomotor symptoms (hot flashes) compared to placebo administration in postmenopausal women.
- Trial name
- NCT00317148
- Testing
- DHEA capsule
- Where
- Canada
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- CHU de Quebec-Universite Laval
Vasomotor System
ZK283197 for Treatment of Vasomotor Symptoms
The primary goal of the planned study is to investigate the efficacy and safety of ZK 283197 in the dosage of 2 and 3 mg ingested once daily during a period of 8 weeks for the treatment of hot flushes.
- Trial name
- NCT00537836
- Testing
- BAY 86-5310 (ZK 283197), 17ß-estradiol
- Where
- 4 sites in Germany, Netherlands and 1 more
- Volunteers
- 116 people
- Sponsor
- Bayer
Menopausal and Female Climacteric States
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
The purpose of this study is to determine whether GSK232802 is safe and effective in reducing the frequency and severity of hot flashes associated with menopause.
- Trial name
- NCT00604825
- Testing
- GSK232802, PREMARIN
- Where
- 87 sites in United States, Argentina and 7 more
- Volunteers
- 356 people
- Sponsor
- GlaxoSmithKline
Breast Cancer, Hot Flashes
Effect of Non-estrogenic Pollen Extract PCC-100 on Hot Flushes
Many postmenopausal women have vasomotor symptoms during adjuvant hormonal treatment for breast cancer. PCC-100 is a pollen extract used for alleviation of postmenopausal symptoms.
- Conditions
- Breast Cancer, Hot Flashes, Postmenopausal Symptoms
- Trial name
- NCT03684096
- Testing
- non-estrogenic pollen extract PCC-100
- Where
- Belgium
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- University Hospital, Ghent
Menopause, Hot Flashes
Acupuncture for Hot Flushes in Menopause
In a pragmatic study investigate whether Traditional Chinese Medicine acupuncture-care decreases the frequency of hot flushes and increases health related quality of life among postmenopausal women.
- Trial name
- ACUFLASH (NCT00284492)
- Testing
- Traditional chinese medicine type acupuncture, Self Care
- Where
- Norway
- Volunteers
- 286 people, healthy volunteers welcome
- Sponsor
- University Hospital of North Norway
Hot Flashes
Efficacy and Safety Study in Postmenopausal Women to Determine the Lowest Effective Dose for Relief of Moderate to Severe Hot-Flushes
To determine the lowest effective dose of estradiol by comparing E2/LNG (2.2mg/0.69mg) and E2 (1.0mg) dose with placebo in decreasing the frequency and severity of moderate to severe hot flushes in postmenopausal women
- Trial name
- NCT00206622
- Testing
- Climara PRO (Estradiol / Levonorgestrel transdermal), Menostar (Estradiol transdermal)
- Where
- 45 sites in United States
- Volunteers
- 425 people
- Sponsor
- Bayer
Hot Flashes, Hot Flash
Herbal Dietary Supplementation on Vasomotor Symptoms in Menopausal Women
The goal of this study is to evaluate the efficacy of a neurokinin 1,3 antagonist on improving vasomotor symptoms (VMS) and overall menopause symptoms in women between the ages of 40-70.
- Conditions
- Hot Flashes, Hot Flash, Hot Flushes, Menopause, Postmenopause, Hot Flushes and/or Sweats
- Trial name
- NCT07408115
- Testing
- JDS-HF3.0
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- Bonafide Health
Postmenopausal Symptoms, Hot Flashes
WHAT (Women, Hot-flashes, Activity, Trial) - Physical Activity for Treatment of Hot Flushes Among Postmenopausal Women
More than 60 % of women experience hot-flashes during postmenopausal and 20 % have serious symptoms. Use of combined estrogen/progesterone therapy reduces hot-flashes effectively.
- Trial name
- WHAT (NCT01282320)
- Testing
- Physical activity intervention program
- Where
- Norway
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University Hospital of North Norway
Hot Flashes
Safety and Efficacy of Dr. Tagliaferri's Menopause Formula
The primary goal of this study is to evaluate the safety and efficacy of 12 weeks of treatment of 4 grams/day of Dr. Tagliaferri's Menopause Formula (administered as 2 grams PO BID) in reducing the frequency of menopausal…
- Trial name
- NCT01957306
- Testing
- Dr. Tagliaferri's Menopause Formula
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Herba Buena, Inc
Postmenopausal Flushing, Hot Flashes
Reflexology Versus Acupressure on Sleep Disturbance and Hot Flashes
World health Organization (WHO) estimates that by 2030, 1.2 billion women will be over 50 years old. With a prevalence of 70%, a hot flash is the most distressing symptoms associated with menopause.
- Trial name
- NCT06499311
- Testing
- Foot Reflexology, Acupressure
- Where
- Egypt
- Volunteers
- 54 people
- Sponsor
- Cairo University
Postmenopausal Flushing, Cardiovascular Risk Factor
Hot Flash as a Marker of Cardiovascular Risk in Recent Postmenopause: Effects of Non-hormonal Treatments
Hot flashes, vasomotor symptoms that affect many postmenopausal women, are associated with cardiovascular disease and endothelial dysfunction.
- Conditions
- Postmenopausal Flushing, Cardiovascular Risk Factor, Endothelial Dysfunction
- Trial name
- NCT03149419
- Testing
- Paroxetine
- Where
- Brazil
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Rio de Janeiro State University
Vasomotor Symptoms, Menopausal Symptoms
Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort II)
A two-part study designed to evaluate the effect of Estetrol (E4) 15 mg, 20 mg, or placebo on the severity and frequency of vasomotor symptoms (VMS) in the Efficacy Study Part and the safety of E4 20 mg in the Safety Study Part.
- Trial name
- E4Comfort II (NCT04090957)
- Testing
- Estetrol oral tablet
- Where
- 117 sites in United States, Canada
- Volunteers
- 1,015 people, healthy volunteers welcome
- Sponsor
- Estetra